Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Acute Nonlymphocytic Leukemia Age: less than 60 years old Condition: First course |
Dose: Intravenous push – 45 mg/m² Frequency: Days 1, 2, 3 Note: In combination with cytarabine 100 mg/m²/day intravenous for 7 days |
|
Indication: Acute Nonlymphocytic Leukemia Age: less than 60 years old Condition: Subsequent courses |
Dose: Intravenous push – 45 mg/m² Frequency: Days 1, 2 Note: In combination with cytarabine 100 mg/m²/day intravenous for 5 days |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Acute Nonlymphocytic Leukemia Age: less than 2 years old |
Dose: Intravenous push – 1 mg/kg Frequency: every week |
|
Indication: Acute Nonlymphocytic Leukemia Age: greater than 2 years old |
Dose: Intravenous push – 25 mg/m² Frequency: every week |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal Impairment greater than 3 mg/dL serum creatinine |
Dose: Administer 50% regular dose Note: Renal Impairment greater than 3 mg/dL serum creatinine: Administer 50% regular dose |
Administration
- For hospital use only
- Must be given by IV
Side Effect
- Nausea
- Vomiting
- Arrhythmias
- Discoloration of urine
- Alopecia
- Injection site skin flare
- Hyperuricemia
- GI ulceration
- Diarrhea
- Arrythmia
- Cardiomyopathy
- Bilirubin increased
- Pruritus
- Urticaria
- Fever
- CHF
- Flushing
- Stomatitis
- Myelosuppression
- Rash
- Hyperpigmentation of previously radiated areas
- Transverse pigmentation of fingernails and toenails
- Fertility impairment
- Bone marrow suppression
- cardiac toxicity
- cardiomyopathy and congestive heart failure
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Cyclophosphamide
|
Increased risk of cardiotoxicity
|
|
Hepatotoxic drugs (e.g. high-dose methotrexate)
|
Increased risk of hepatic toxicity
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Heart Failure
|
Can worsen heart condition
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store unopened vials in the refrigerator, 2°-8°C. Contains no preservatives. Discard unused portions. Protect from light. If Daunorubicin contacts the skin or mucosae, the area should be washed thoroughly with soap and water. Procedures for proper handling and disposal of anticancer drugs should be considered.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.